Scandinavian ChemoTech AB Series B (CMOTEC-B) - Cash Flow Conversion Efficiency

Latest as of June 2026: -1.171x

Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has a cash flow conversion efficiency ratio of -1.171x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.78 Million ≈ $-191.56K USD) by net assets (Skr1.52 Million ≈ $163.58K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Scandinavian ChemoTech AB Series B for the company's overall valuation and market capitalisation.

Scandinavian ChemoTech AB Series B - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Scandinavian ChemoTech AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Scandinavian ChemoTech AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Scandinavian ChemoTech AB Series B to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
ASKOLL EVA S.P.A. F:736	N/A
Swift Networks Group Ltd AU:SW1	-0.012x
Dnonce Tech Bhd KLSE:7114	0.031x
ICDS Limited NSE:ICDSLTD	0.021x
Harper Hygienics S.A. WAR:HRP	0.013x
Canterbury Resources Ltd AU:CBY	-0.060x
Churchill Resources Inc V:CRI	-0.401x
Celsius Resources Limited F:FX8	-0.046x

Annual Cash Flow Conversion Efficiency for Scandinavian ChemoTech AB Series B (2014–2025)

The table below shows the annual cash flow conversion efficiency of Scandinavian ChemoTech AB Series B from 2014 to 2025. View CMOTEC-B live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr3.19 Million ≈ $342.86K	Skr-3.75 Million ≈ $-403.02K	-1.175x	+46.53%
2024-12-31	Skr5.98 Million ≈ $643.54K	Skr-13.14 Million ≈ $-1.41 Million	-2.198x	-33.04%
2023-12-31	Skr11.03 Million ≈ $1.19 Million	Skr-18.23 Million ≈ $-1.96 Million	-1.652x	-17.77%
2022-12-31	Skr13.99 Million ≈ $1.51 Million	Skr-19.63 Million ≈ $-2.11 Million	-1.403x	-74.92%
2021-12-31	Skr23.92 Million ≈ $2.57 Million	Skr-19.18 Million ≈ $-2.06 Million	-0.802x	+12.79%
2020-12-31	Skr9.24 Million ≈ $993.94K	Skr-8.49 Million ≈ $-914.09K	-0.920x	+20.30%
2019-12-31	Skr9.73 Million ≈ $1.05 Million	Skr-11.23 Million ≈ $-1.21 Million	-1.154x	-416.46%
2018-12-31	Skr20.50 Million ≈ $2.21 Million	Skr-4.58 Million ≈ $-492.77K	-0.223x	+84.65%
2017-12-31	Skr10.29 Million ≈ $1.11 Million	Skr-14.97 Million ≈ $-1.61 Million	-1.456x	-182.40%
2016-12-31	Skr14.58 Million ≈ $1.57 Million	Skr-7.52 Million ≈ $-808.93K	-0.515x	+5.74%
2015-12-31	Skr868.64K ≈ $93.48K	Skr-474.99K ≈ $-51.12K	-0.547x	+38.15%
2014-12-31	Skr46.27K ≈ $4.98K	Skr-40.91K ≈ $-4.40K	-0.884x	--

About Scandinavian ChemoTech AB Series B

ST:CMOTEC-B Sweden Biotechnology

Market Cap

$8.71 Million

Skr80.93 Million SEK

Market Cap Rank

#27518 Global

#599 in Sweden

Share Price

Skr3.40

Change (1 day)

+5.92%

52-Week Range

Skr3.04 - Skr7.30

All Time High

Skr51358.02